Abstract：
BACKGROUND: During the COVID-19 pandemic, the need for digital pathology tools became more urgent. However, there needs to be more knowledge of the use in cytology. We aimed to evaluate current digital cytology practices and attitudes and compare the results with a pre-COVID-19 American Society of Cytopathology (ASC) survey.
METHODS: Fourteen survey questions assessing current attitudes toward digital cytology were developed from a 2016 ASC Digital Pathology Survey. Ten new survey questions were also created to evaluate telecytology use. The survey was e-mailed to ASC members over 6 weeks in 2023.
RESULTS: A total of 123 individuals responded (116 in 2016). Attitudes toward digital cytology were unchanged; most participants stated digital cytology is beneficial (87% 2023 versus 90% 2016). The percentage of individuals using digital cytology was unchanged (56% in 2016 and 2023). However, telecytology for rapid onsite assessment (ROSE) is now considered the best application (55% 2023 versus 31% 2016). Forty-three institutions reported using digital and telecytology tools; 40% made implementations after 2020; most did not feel that COVID-19 affected digital cytology (56%). Telecytology for ROSE is the most common application now (78%) compared with education (30%) in 2016. Limitations for implementing digital imaging in cytology included inability to focus (38%) and expense (33%).
CONCLUSIONS: General attitudes toward digital tools by the cytology community have essentially remained the same between 2016 and now. However, telecytology for ROSE is increasingly being used, which supports a need for validation and competency guidelines.
METHODS: Fourteen survey questions assessing current attitudes toward digital cytology were developed from a 2016 ASC Digital Pathology Survey. Ten new survey questions were also created to evaluate telecytology use. The survey was e-mailed to ASC members over 6 weeks in 2023.
RESULTS: A total of 123 individuals responded (116 in 2016). Attitudes toward digital cytology were unchanged; most participants stated digital cytology is beneficial (87% 2023 versus 90% 2016). The percentage of individuals using digital cytology was unchanged (56% in 2016 and 2023). However, telecytology for rapid onsite assessment (ROSE) is now considered the best application (55% 2023 versus 31% 2016). Forty-three institutions reported using digital and telecytology tools; 40% made implementations after 2020; most did not feel that COVID-19 affected digital cytology (56%). Telecytology for ROSE is the most common application now (78%) compared with education (30%) in 2016. Limitations for implementing digital imaging in cytology included inability to focus (38%) and expense (33%).
CONCLUSIONS: General attitudes toward digital tools by the cytology community have essentially remained the same between 2016 and now. However, telecytology for ROSE is increasingly being used, which supports a need for validation and competency guidelines.
摘要：
背景：在COVID-19大流行期间，对数字病理学工具的需求变得更加迫切。然而,需要更多的细胞学知识。我们旨在评估当前的数字细胞学实践和态度，并将结果与COVID-19之前的美国细胞病理学学会（ASC）调查进行比较。
方法：评估当前对数字细胞学态度的十四个调查问题来自2016年ASC数字病理学调查。还创建了十个新的调查问题来评估电信使用情况。该调查在2023年的6周内通过电子邮件发送给ASC成员。
结果：共有123人做出回应（2016年为116人）。对数字细胞学的态度没有改变;大多数参与者表示数字细胞学是有益的(2023年为87%，2016年为90%)。使用数字细胞学的个人比例没有变化（2016年和2023年为56％）。然而,远程快速现场评估（ROSE）现在被认为是最佳应用（2023年为55%，2016年为31%）。43个机构报告使用数字和电信工具；40%在2020年后实施；大多数人认为COVID-19没有影响数字细胞学（56%）。与2016年的教育（30％）相比，ROSE的远程学习是现在最常见的应用（78％）。在细胞学中实施数字成像的局限性包括无法聚焦（38％）和费用（33％）。
结论：从2016年到现在，细胞学界对数字工具的总体态度基本保持不变。然而,ROSE的电信学越来越多地被使用，这支持对验证和能力准则的需求。
方法：评估当前对数字细胞学态度的十四个调查问题来自2016年ASC数字病理学调查。还创建了十个新的调查问题来评估电信使用情况。该调查在2023年的6周内通过电子邮件发送给ASC成员。
结果：共有123人做出回应（2016年为116人）。对数字细胞学的态度没有改变;大多数参与者表示数字细胞学是有益的(2023年为87%，2016年为90%)。使用数字细胞学的个人比例没有变化（2016年和2023年为56％）。然而,远程快速现场评估（ROSE）现在被认为是最佳应用（2023年为55%，2016年为31%）。43个机构报告使用数字和电信工具；40%在2020年后实施；大多数人认为COVID-19没有影响数字细胞学（56%）。与2016年的教育（30％）相比，ROSE的远程学习是现在最常见的应用（78％）。在细胞学中实施数字成像的局限性包括无法聚焦（38％）和费用（33％）。
结论：从2016年到现在，细胞学界对数字工具的总体态度基本保持不变。然而,ROSE的电信学越来越多地被使用，这支持对验证和能力准则的需求。
